Advertisment

Redefining Standards: FDA's New Proposals for Pulse Oximeters Aiming at Accuracy for All Skin Pigments

author-image
Zara Nwosu
New Update
NULL

Redefining Standards: FDA's New Proposals for Pulse Oximeters Aiming at Accuracy for All Skin Pigments

Advertisment

The U.S. Food and Drug Administration (FDA) is considering the implementation of new standards for pulse oximeters, a crucial medical device that measures oxygen saturation levels in the blood. The goal of these proposed changes is to ensure that the devices accurately measure blood oxygen levels in individuals of all skin pigments. This initiative comes in response to recent concerns that the accuracy of pulse oximeters varies with skin pigmentation, leading to potential disparities in healthcare outcomes.

Advertisment

Higher Accuracy Standards for Pulse Oximeters

As per the new standards announced by the FDA, pulse oximeters are required to meet higher accuracy standards. The objective of these regulations is to enhance the performance and reliability of pulse oximeters used in medical settings. Alongside this, the FDA has issued warnings about the potential risks associated with using pulse oximeters that fail to meet these new standards.

New Standards Focus on Performance Testing

Advertisment

These new standards place a significant emphasis on performance testing. This includes identifying accuracy levels in different patient populations and under various conditions. The ultimate goal is to guarantee that pulse oximeters provide reliable and accurate readings for all patients, with a particular focus on those with darker skin tones. To enforce these standards, the FDA is in the process of establishing new regulations that pulse oximeter manufacturers must adhere to.

Increased Diversity in Clinical Trials

The FDA panel recommends greater diversity in pulse oximeter trials. This is intended to evaluate the accuracy and performance of pulse oximeters more effectively in patients with darker skin tones. Current research suggests that if pulse oximeters are not calibrated for darker skin tones, they could deliver inaccurate oxygen readings. Proposals are under consideration to revise clinical trials to include a more diverse group of people, with at least 24 participants representing the full range of skin tones on the 10 shade Monk Skin Tone scale.

Advertisment

Addressing the Bias in Pulse Oximeters

The FDA is reigniting the discussion over biased pulse oximeters and planning to continue the debate on making these devices more accurate for people with darker skin. Emerging evidence suggests that these devices may not consistently detect low oxygen levels in Black patients, leading to delayed care and missed diagnoses. The FDA is proposing updated standards for clinical studies to include a more inclusive and representative patient population. This move is particularly significant considering the increasing role of pulse oximeters in consumer tech and their relevance in a patent dispute between tech giant Apple and medical technology company Masimo.

Improving Accuracy for Darker Skin Pigments

The FDA's Anesthesiology and Respiratory Therapy Devices Panel is discussing ways to improve the accuracy of pulse oximeters, particularly for patients with darker skin pigments. This action is a response to the increased use of pulse oximeters during the COVID-19 pandemic, which brought to light the limitations and risks associated with the technology for patients with darker skin. As a result, the FDA is considering updating their 2013 guidance to pulse oximeter manufacturers and seeking input on the design of a premarket clinical trial to improve the quality of premarket studies.

In conclusion, the FDA's proposed changes to pulse oximeter standards aim to ensure equity and accuracy in healthcare by accounting for variations in skin pigmentation. By implementing these changes, the FDA hopes to mitigate disparities in healthcare outcomes and improve patient safety across all skin tones.

Advertisment
Chat with Dr. Medriva !